Ad is loading...
MENU

SLDB Stock Solid Biosciences (SLDB, $5) RSI Indicator left the oversold zone on November 18, 2024

A.I.dvisor
at Tickeron.com
Loading...
SLDB - Solid Biosciences
RSI signal
Bullish Trend
Odds of UP Trend
Tickeron
RSI signal
Price: $5
Daily change: +$0.15 (+3.09%)
Daily volume: 567.8K
Industry: Biotechnology
This is a signal that SLDB's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options. A.I.dvisor looked back and found 47 similar cases where SLDB's RSI Indicator left the oversold zone, and in of them led to a successful outcome. Odds of Success:

SLDB's RSI Oscillator ascending out of oversold territory

The RSI Indicator for SLDB moved out of oversold territory on November 18, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 47 similar instances when the indicator left oversold territory. In of the 47 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where SLDB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

SLDB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on SLDB as a result. In of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SLDB turned negative on November 15, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SLDB entered a downward trend on November 21, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.251) is normal, around the industry mean (13.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.241). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.798). SLDB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (221.024).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SLDB
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of novel gene therapy platform for advancing disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
500 Rutherford Avenue
Phone
+1 617 337-4680
Employees
88
Web
https://www.solidbio.com